Core Viewpoint - The company, Xinlitai (002294.SZ), has received approval from the National Medical Products Administration for clinical trials of its innovative small molecule drug SAL0137, aimed at treating elevated lipoprotein(a) levels, which are independent risk factors for various cardiovascular diseases [1] Group 1 - The clinical trial approval allows the company to advance its research on SAL0137, which has shown potential in preclinical studies for treating elevated lipoprotein(a) [1] - Elevated lipoprotein(a) levels are linked to increased risks of coronary heart disease, ischemic stroke, peripheral vascular disease, coronary artery calcification, and calcific aortic valve stenosis [1] - The mechanisms by which lipoprotein(a) increases cardiovascular disease risk include promoting atherosclerosis, inflammation, and thrombosis [1]